Background. The single-nucleotide polymorphism CYP3A5 rs776746 is related to a
reduction in the metabolizing activity of the CYP3A5 enzyme. People carrying at least one …

Background Tacrolimus is essential for the maintenance of immunosuppression after a
kidney transplant. CYP3A5 is the gene that metabolizes tacrolimus, and polymorphism in …

Objective Patients expressing the tacrolimus-metabolizing enzyme, cytochrome P450 (CYP)
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …

Background After renal transplantation, immunosuppressants should be administered to
prevent organ rejection and prolong graft survival. One of them is tacrolimus, which is …

Introduction: Although the association between CYP3A5 gene polymorphism and tacrolimus
dosing requirements was well established, the impact on how CYP3A5 genotype affects the …

Purpose We assessed reported associations of CYP3A5* 1 allele with a delay in achieving
target tacrolimus concentrations, and occurrence of biopsy-confirmed subclinical acute …

Aim: Meta-analyses and large cohort studies provide confusing results on the association of
the CYP3A5 6986A> G allelic variant and adverse outcomes in kidney transplant recipients …

Background. Tacrolimus is a major immunosuppressant, which has a narrow therapeutic
range and wide interindividual variation. The effects of genetic polymorphisms of …

Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a
narrow therapeutic range and demonstrates wide interindividual variability in …

OBJECTIVE: Tacrolimus concentrations are associated with CYP3A5 genotype. The
purpose of this study was to evaluate the outcomes and drug concentrations/doses among a …